Regeneron Pharmaceuticals (REGN) Debt to Equity (2020 - 2026)

Regeneron Pharmaceuticals' Debt to Equity history runs 7 years deep, the most recent figure standing at $0.06 for Q1 2026.

• In Q1 2026, Debt to Equity fell 6.41% year-over-year to $0.06; the TTM figure through Mar 2026 stood at $0.06 (down 6.41% YoY), while the FY2025 annual figure was $0.06, down 6.01% from the prior year.
• Debt to Equity was $0.06 for Q1 2026 at Regeneron Pharmaceuticals, down from $0.06 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $0.1 in Q1 2022 to a low of $0.06 in Q1 2026.
• Historically, Debt to Equity has averaged $0.08 across 5 years, with a median of $0.07 in 2024.
• The sharpest annual moves came in 2022 and 2025: Debt to Equity plunged 39.81% in 2022, then decreased 5.2% in 2025.
• A 5-year view of Debt to Equity shows it stood at $0.09 in 2022, then slipped by 12.67% to $0.08 in 2023, then slipped by 11.45% to $0.07 in 2024, then fell by 6.01% to $0.06 in 2025, then declined by 0.52% to $0.06 in 2026.
• The last three Debt to Equity figures came in at $0.06 (Q1 2026), $0.06 (Q4 2025), and $0.06 (Q3 2025), per Business Quant data.